VEGFA and neoplasm: Non-clinical studies have demonstrated that bevacizumab, an antiangiogenic targeted agent, can inhibit vascular endothelial growth factor, promote tumor vascular normalization, increase T cell infiltration, and reduce immunosuppressive cell activity, thereby improving immunotherapy efficacy [10].